Versatility is a must-have trait to have in leadership. Unfortunately, however, with the specialized nature of modern business, it is quite rare to find business leaders who exemplify this trait. One of the few who does is Foresite Capital founder and chief executive officer, Jim Tananbaum. The medical doctor has been involved as an investor in 21 companies involved in various spheres within the healthcare industry.
Mr. Tananbaum’s fascinating peculiarity and versatility are seen right from his educational background. He received a Bachelor of Science in Electrical Engineering and Bachelor of Science degree from Yale University. He then went on to the Massachusetts Institute of Technology where he received a Master of Science, in Health Sciences and Technology degree. He studied for his masters while concurrently attending Harvard Medical School, from where he was awarded a Doctor of Medicine (MD) degree. Immediately after he joined the MBA program at Harvard Business School, completing two years later. This 10-year long educational journey that straddled between the fields of engineering, medicine, and business adequately prepared Mr. Tananbaum to become the investor and leader he is today. Visit LinkedIn to know more.
Mr. Tananbaum’s entrepreneurial exploits did not begin with Foresite Capital. He had long before invested in two pharmaceutical companies that would go on to be significantly successful. The first, GelTex Pharmaceuticals was worth a few million dollars when he invested in it. By the time of its sale, however, it was valued at $1.6 billion. The other company that he had founded was Theravance. He served at the company’s helm for three years, a period which saw its fortunes and value rise significantly. Theravance is still a significant player in the pharmaceutical industry till this day. Before settling at Foresite Capital, Mr. Tananbaum co-founded and managed Prospect Venture Partners.
Due to his ability to deliver, Mr. Jim Tananbaum has been invited to sit on a number of companies’ boards of directors. He sits on the board of Tarsa Therapeutics and also serves as an investor to Amerigroup, Amira Pharmaceuticals, and Jazz Pharmaceuticals. Further, he also sits on the advisory boards of Yale School of Engineering and the Harvard-MIT Health Sciences and Technology program.